Geoffrey L. Uy, MD: Investigating Flotetuzumab in AML and MDS
722 views · Published 11 December 2017 · 5:52 · Indexed 12 November 2026
Channel: American Society of Hematology · 2017 · Nonprofits & Activism
Dr. Uy discusses preliminary results from a phase I trial of flotetuzumab, a CD123 x CD3 bispecific DART protein, in patients with relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes, as well as the challenges of finding new targets in AML.
More from this channel
-
1:52
Ron Reagan Accepts ASH Award - Stem Cell Research
-
4:25
Sen. Jim Talent's Work on Sickle Cell Disease Legislation
-
3:56
ASH and the Reagans Support Stem Cell Research
-
5:42
The American Society of Hematology Celebrates its 50th Anniversary
-
5:57
David Nathan Receives 2011 Wallace H. Coulter Award for Lifetime Achievement in Hematology
-
5:17
James George Receives 2012 Wallace H. Coulter Award for Lifetime Achievement in Hematology
-
2:21
Congress: Protect NIH funding
-
2:21
Act Now: Tell Congress to Stop Further Cuts to Research Funding